Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.

Literature DB >> 22072492

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.

Sophie Dimicoli¹, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Zeev Estrov, Hui Yang, Mary Kelly, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 22072492 PMCID： PMC4085038 DOI： 10.1002/ajh.22198

Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047

× No keyword cloud information.

11 in total

Review 1. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.

Authors: Guillermo Garcia-Manero; Jean-Pierre Issa
Journal: Cancer Invest Date: 2005 Impact factor: 2.176

Review 2. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

Authors: Guillermo Garcia-Manero; Pierre Fenaux
Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544

3. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Authors: Francis Giles; Thomas Fischer; Jorge Cortes; Guillermo Garcia-Manero; Joachim Beck; Farhad Ravandi; Eric Masson; Patricia Rae; Glen Laird; Sunil Sharma; Hagop Kantarjian; Margaret Dugan; Maher Albitar; Kapil Bhalla
Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531

4. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors: Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245

5. International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal: Blood Date: 1997-03-15 Impact factor: 22.113

6. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

Authors: Martin Jädersten; Scott M Montgomery; Ingunn Dybedal; Anna Porwit-MacDonald; Eva Hellström-Lindberg
Journal: Blood Date: 2005-04-19 Impact factor: 22.113

7. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal: Blood Date: 2006-04-11 Impact factor: 22.113

Review 8. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.

Authors: Guillermo Garcia-Manero
Journal: Am J Hematol Date: 2011-06 Impact factor: 10.047

9. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Authors: Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz
Journal: Blood Date: 2004-03-23 Impact factor: 22.113

10. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.

Authors: J X Zou; D E Rollison; D Boulware; D-T Chen; E M Sloand; L V Pfannes; J J Goronzy; F Bai; J S Painter; S Wei; D Cosgrove; A F List; P K Epling-Burnette
Journal: Leukemia Date: 2009-03-12 Impact factor: 12.883

11 in total

Review 1. Panobinostat: first global approval.

Authors: Karly P Garnock-Jones
Journal: Drugs Date: 2015-04 Impact factor: 9.546

2. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.

Authors: John H Strickler; Alexander N Starodub; Jingquan Jia; Kellen L Meadows; Andrew B Nixon; Andrew Dellinger; Michael A Morse; Hope E Uronis; P Kelly Marcom; S Yousuf Zafar; Sherri T Haley; Herbert I Hurwitz
Journal: Cancer Chemother Pharmacol Date: 2012-06-29 Impact factor: 3.333

3. Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years.

Authors: Uma Borate; Brianna A Norris; Abby Statler; Rongwei Fu; Taylor Bucy; Mikkael A Sekeres
Journal: Blood Adv Date: 2019-09-24

Review 4. Current therapy of myelodysplastic syndromes.

Authors: Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal: Blood Rev Date: 2013-07-27 Impact factor: 8.250

5. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.

Authors: Yukio Kobayashi; Wataru Munakata; Michinori Ogura; Toshiki Uchida; Masafumi Taniwaki; Tsutomu Kobayashi; Fumika Shimada; Masataka Yonemura; Fumiko Matsuoka; Takeshi Tajima; Kimikazu Yakushijin; Hironobu Minami
Journal: Int J Hematol Date: 2017-09-13 Impact factor: 2.490